EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Industry‐sponsored meal payments are associated with prescriptions and Medicare expenditures on brand‐name colchicine in the United States

Anju Murayama iD

International Journal of Rheumatic Diseases · 2024

DOI: 10.1111/1756-185x.14962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Anju Murayama. Beteiligte Einrichtung: School of Medicine, Tohoku University, Sendai City, Japan. Hauptthemen laut MEDLINE: Prescription Drugs, Medicare Part D. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the association between industry‐sponsored meal payments and the prescribing patterns of brand‐name colchicines, namely Colcrys and Mitigare, among Medicare beneficiaries in the United States from 2014 to 2021.

Methods

This cross‐sectional study utilized data from the Open Payments Database and Medicare Part D covering the years 2014 to 2021. The study included 54 836 physicians who submitted more than 10 colchicine claims. Exposure was defined as the receipt of one or more industry‐sponsored meals from the manufacturers of Colcrys or Mitigare. The primary outcomes included the likelihood of prescribing Colcrys and Mitigare, as well as the associated number of claims and Medicare expenditures.

Results

Among 54 836 eligible physicians, 44.9% received meal payments from the Colcrys manufacturer, and 8.0% from the Mitigare manufacturer, over the eight‐year study period. The average meal payment value was $14.9 for Colcrys and $15.1 for Mitigare. The receipt of meal payments was significantly associated with an increased likelihood of prescribing Colcrys (odds ratio: 1.24 [95% CI: 1.21–1.27], p < .001) and Mitigare (odds ratio: 3.54 [95% CI: 2.98–4.20], p < .001). Each additional meal payment corresponded with a significant increase in Medicare expenditures: $55.4 (95% CI: $48.3–$62.5, p < .001) for Colcrys and $153.7 (95% CI: $17.7–$289.6, p = .03) for Mitigare. These associations remained consistent across different specialties and genders.

Conclusion

This study reveals that receipt of meal payments from manufacturers of brand‐name colchicine was significantly associated with an increased rate of prescriptions for these brand‐name drugs, leading to higher Medicare expenditures in the United States.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prescription DrugsMedicare Part DAgedHumansUnited StatesMaleFemaleColchicineHealth ExpendituresCross-Sectional StudiesPractice Patterns, Physicians'PrescriptionsDrug Industry

Stichwörter der Autor:innen

United Statescolchicineconflicts of interestgouthealth policyindustry paymentrheumatology

Substanzen

ColchicinePrescription Drugs

Autor:innen und Institutionen

  • School of Medicine, Tohoku University, Sendai City, Japan.
  • Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Anju Murayama

Zitieren

APA

Murayama, A. (2024). Industry‐sponsored meal payments are associated with prescriptions and Medicare expenditures on brand‐name colchicine in the United States. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.14962

Vancouver

Murayama A. Industry‐sponsored meal payments are associated with prescriptions and Medicare expenditures on brand‐name colchicine in the United States. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.14962

BibTeX
@article{Murayama2024,
  author = {Murayama, Anju},
  title = {Industry‐sponsored meal payments are associated with prescriptions and Medicare expenditures on brand‐name colchicine in the United States},
  journal = {International Journal of Rheumatic Diseases},
  year = {2024},
  doi = {10.1111/1756-185x.14962}
}
Kostenlos starten →